AbbVie Inc.'s third-quarter revenue from its immunology portfolio was $5.79 billion, a 14.8% increase year over year. That result included revenue from AbbVie's Humira medication of $5.14 billion, a figure that rose 4.1% year over year. "AbbVie Logs 3Q Sales Growth on Higher Immunology, Oncology Results," published at 8:07 a.m. ET, incorrectly said that immunology revenue increased 4.1%, to $5.14 billion.

 

(END) Dow Jones Newswires

October 30, 2020 09:50 ET (13:50 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more AbbVie Charts.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more AbbVie Charts.